Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: January 13, 2026
Dapivirine + Copper + Zinc IVR MPT
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Queen's University Belfast
Active
Last updated: January 13, 2026
Oral Levonorgestrel and Meloxicam On Demand Pill

IG002

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Pericoital
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): InnovaGyn, Inc.
Active
Last updated: January 13, 2026
EP055 In-Situ Forming Implant
  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of North Carolina
Active
Last updated: January 13, 2026
Non-Hormonal Vaginal Ring

The Better Ring

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Elle MD Biotechnologies
Active
Last updated: January 13, 2026
Non-Hormonal Electrospun Mesh MPT
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Lagos
Inactive
Last updated: January 13, 2026
Weekly Combined Oral Contraceptive
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Lyndra Therapeutics, Massachusetts Institute of Technology
Active
Last updated: January 13, 2026
Daily Oral Ulipristal Acetate

ROC

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Short-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): Contraceptive Clinical Trials Network, NICHD, HRA Pharma
Active
Last updated: January 13, 2026
Serine Protease Inhibitor

4-(2-Aminoethyl)Benzenesulfonyl Fluoride (AEBSF), KLK3 Inhibitors

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Washington State University
Inactive
Last updated: January 7, 2026
Copper + LDPE Nanocomposite IUD

Cu/LDPE/MVQ IUD

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Intrauterine
  • Intended Duration: Long-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): Tongji Medical College at Huazhong University of Science and Technology Dayu Medical Devices
Active
Last updated: January 7, 2026
Wondaleaf Unisex Condom
  • User: Female/Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Barrier
  • Intended Duration: Pericoital
  • Development Stage: Single-Country Approval
  • Developer(s)/Researcher(s): MRU - University of Witwatersrand, Twin Catalyst Sdn Bhd